Publication

Dasatinib in combination with fludaralaine in patients with refractory chronic lymphocytic leukemia: A multicenter phase 2 study

Kater, A. P., Spiering, M., Liu, R. D., te Raa, G. D., Slinger, E., Tonino, S. H., Beckers, M. M., Daenen, S., Doorduijn, J. K., Lankheet, N. A. G., Luijks, D. M., Eldering, E. & van Oers, M. H. J., Jan-2014, In : Leukemia Research. 38, 1, p. 34-41 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Kater, A. P., Spiering, M., Liu, R. D., te Raa, G. D., Slinger, E., Tonino, S. H., ... van Oers, M. H. J. (2014). Dasatinib in combination with fludaralaine in patients with refractory chronic lymphocytic leukemia: A multicenter phase 2 study. Leukemia Research, 38(1), 34-41. https://doi.org/10.1016/j.leukres.2013.10.004

Author

Kater, Arnon P. ; Spiering, Marjolein ; Liu, Roberto D. ; te Raa, G. Doreen ; Slinger, E. ; Tonino, Sanne H. ; Beckers, Marielle M. ; Daenen, Simon ; Doorduijn, Jeanette K. ; Lankheet, Nienke A. G. ; Luijks, Dieuwertje M. ; Eldering, Eric ; van Oers, Marnius H. J. / Dasatinib in combination with fludaralaine in patients with refractory chronic lymphocytic leukemia : A multicenter phase 2 study. In: Leukemia Research. 2014 ; Vol. 38, No. 1. pp. 34-41.

Harvard

Kater, AP, Spiering, M, Liu, RD, te Raa, GD, Slinger, E, Tonino, SH, Beckers, MM, Daenen, S, Doorduijn, JK, Lankheet, NAG, Luijks, DM, Eldering, E & van Oers, MHJ 2014, 'Dasatinib in combination with fludaralaine in patients with refractory chronic lymphocytic leukemia: A multicenter phase 2 study', Leukemia Research, vol. 38, no. 1, pp. 34-41. https://doi.org/10.1016/j.leukres.2013.10.004

Standard

Dasatinib in combination with fludaralaine in patients with refractory chronic lymphocytic leukemia : A multicenter phase 2 study. / Kater, Arnon P.; Spiering, Marjolein; Liu, Roberto D.; te Raa, G. Doreen; Slinger, E.; Tonino, Sanne H.; Beckers, Marielle M.; Daenen, Simon; Doorduijn, Jeanette K.; Lankheet, Nienke A. G.; Luijks, Dieuwertje M.; Eldering, Eric; van Oers, Marnius H. J.

In: Leukemia Research, Vol. 38, No. 1, 01.2014, p. 34-41.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Kater AP, Spiering M, Liu RD, te Raa GD, Slinger E, Tonino SH et al. Dasatinib in combination with fludaralaine in patients with refractory chronic lymphocytic leukemia: A multicenter phase 2 study. Leukemia Research. 2014 Jan;38(1):34-41. https://doi.org/10.1016/j.leukres.2013.10.004


BibTeX

@article{33c3f51f76664eb5af583a0b512c1ddd,
title = "Dasatinib in combination with fludaralaine in patients with refractory chronic lymphocytic leukemia: A multicenter phase 2 study",
abstract = "Resistance to chemotherapy-induced apoptosis in CLL is associated with overexpression of antiapoptotic proteins induced by signals from the microenvironment. In vitro, dasatinib effectively inhibits expression of anti-apoptotic regulators and restores fludarabine sensitivity in activated CLL.The aim of this study was to evaluate efficacy of one cycle of dasatinib monotherapy (100 mg/day, days 1-28) followed by combination of dasatinib with fludarabine (40 mg/m(2)/day, days 1-3 every 28 day) for a total of it cycles in fludarabine-refractory. The primary endpoint was overall response rate according to the IWCLL'08 criteria.20 patients were enrolled: 18 completed at least one cycle of treatment of which 67{\%} finishsed at Pact 2 cycles of combination treatment. 3 of these 18 patients reached a format PR (16,7{\%}). Majority of patients obtained some reduction in lymph node (LN) size. Most frequent toxicity was related to myelosuppression.NF-kappa B RNA expression levels of circulating CLL cells decreased whereas the levels of pro-apoptotic NOXA increased during trot merit.In conclusion, dasatinib/fludarabine combination has modest clinical efficacy in fludarabine-refractory patients. (C) 2013 Elsevier Ltd, All rights reserved.",
keywords = "CLL, Hudarabine refractory, Microenvironment, Kinase inhibitor, Dasatinib, NOXA, KINASE INHIBITOR DASATINIB, B-CELL RECEPTOR, IN-VITRO, NOXA/MCL-1 BALANCE, RESPONSE CRITERIA, TYROSINE KINASE, SALVAGE THERAPY, SINGLE-AGENT, FLUDARABINE, ALEMTUZUMAB",
author = "Kater, {Arnon P.} and Marjolein Spiering and Liu, {Roberto D.} and {te Raa}, {G. Doreen} and E. Slinger and Tonino, {Sanne H.} and Beckers, {Marielle M.} and Simon Daenen and Doorduijn, {Jeanette K.} and Lankheet, {Nienke A. G.} and Luijks, {Dieuwertje M.} and Eric Eldering and {van Oers}, {Marnius H. J.}",
year = "2014",
month = "1",
doi = "10.1016/j.leukres.2013.10.004",
language = "English",
volume = "38",
pages = "34--41",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "PERGAMON-ELSEVIER SCIENCE LTD",
number = "1",

}

RIS

TY - JOUR

T1 - Dasatinib in combination with fludaralaine in patients with refractory chronic lymphocytic leukemia

T2 - A multicenter phase 2 study

AU - Kater, Arnon P.

AU - Spiering, Marjolein

AU - Liu, Roberto D.

AU - te Raa, G. Doreen

AU - Slinger, E.

AU - Tonino, Sanne H.

AU - Beckers, Marielle M.

AU - Daenen, Simon

AU - Doorduijn, Jeanette K.

AU - Lankheet, Nienke A. G.

AU - Luijks, Dieuwertje M.

AU - Eldering, Eric

AU - van Oers, Marnius H. J.

PY - 2014/1

Y1 - 2014/1

N2 - Resistance to chemotherapy-induced apoptosis in CLL is associated with overexpression of antiapoptotic proteins induced by signals from the microenvironment. In vitro, dasatinib effectively inhibits expression of anti-apoptotic regulators and restores fludarabine sensitivity in activated CLL.The aim of this study was to evaluate efficacy of one cycle of dasatinib monotherapy (100 mg/day, days 1-28) followed by combination of dasatinib with fludarabine (40 mg/m(2)/day, days 1-3 every 28 day) for a total of it cycles in fludarabine-refractory. The primary endpoint was overall response rate according to the IWCLL'08 criteria.20 patients were enrolled: 18 completed at least one cycle of treatment of which 67% finishsed at Pact 2 cycles of combination treatment. 3 of these 18 patients reached a format PR (16,7%). Majority of patients obtained some reduction in lymph node (LN) size. Most frequent toxicity was related to myelosuppression.NF-kappa B RNA expression levels of circulating CLL cells decreased whereas the levels of pro-apoptotic NOXA increased during trot merit.In conclusion, dasatinib/fludarabine combination has modest clinical efficacy in fludarabine-refractory patients. (C) 2013 Elsevier Ltd, All rights reserved.

AB - Resistance to chemotherapy-induced apoptosis in CLL is associated with overexpression of antiapoptotic proteins induced by signals from the microenvironment. In vitro, dasatinib effectively inhibits expression of anti-apoptotic regulators and restores fludarabine sensitivity in activated CLL.The aim of this study was to evaluate efficacy of one cycle of dasatinib monotherapy (100 mg/day, days 1-28) followed by combination of dasatinib with fludarabine (40 mg/m(2)/day, days 1-3 every 28 day) for a total of it cycles in fludarabine-refractory. The primary endpoint was overall response rate according to the IWCLL'08 criteria.20 patients were enrolled: 18 completed at least one cycle of treatment of which 67% finishsed at Pact 2 cycles of combination treatment. 3 of these 18 patients reached a format PR (16,7%). Majority of patients obtained some reduction in lymph node (LN) size. Most frequent toxicity was related to myelosuppression.NF-kappa B RNA expression levels of circulating CLL cells decreased whereas the levels of pro-apoptotic NOXA increased during trot merit.In conclusion, dasatinib/fludarabine combination has modest clinical efficacy in fludarabine-refractory patients. (C) 2013 Elsevier Ltd, All rights reserved.

KW - CLL

KW - Hudarabine refractory

KW - Microenvironment

KW - Kinase inhibitor

KW - Dasatinib

KW - NOXA

KW - KINASE INHIBITOR DASATINIB

KW - B-CELL RECEPTOR

KW - IN-VITRO

KW - NOXA/MCL-1 BALANCE

KW - RESPONSE CRITERIA

KW - TYROSINE KINASE

KW - SALVAGE THERAPY

KW - SINGLE-AGENT

KW - FLUDARABINE

KW - ALEMTUZUMAB

U2 - 10.1016/j.leukres.2013.10.004

DO - 10.1016/j.leukres.2013.10.004

M3 - Article

VL - 38

SP - 34

EP - 41

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 1

ER -

ID: 16066568